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INTRODUCTION
Proton pump inhibitors (PPIs) are “drugs of choice” for the 
treatment of acid-related gastrointestinal diseases such as 
benign peptic ulcer and duodenal ulcer, gastroesophageal 
reflux disease (GERD), Zollinger-Elison syndrome [1].
The pharmaceutical market of Ukraine currently of-
fers six international nonproprietary PPIs: Omeprazole 
(A02BC01), Pantoprazole (A02BC02), Lansoprazole 
(A02BC03), Rabeprazole (A02BC04), Esomeprazole 
(A02BC05), Dexlansoprazole (A02BC06) [1].
The basis of the molecular structure of all PPIs is the 
heterocyclic core of benzimidazole, which causes a single 
mechanism of action and the same efficacy of PPIs in the 
treatment of the acid-related diseases of the gastrointestinal 
tract [2].
PPIs differ in the structure of radicals on pyridine and 
benzimidazole cycles, which causes some difference in 
the pharmacokinetic and pharmacodynamic properties of 
these drugs [3, 4]. The peculiarities of the pharmacokinetic 
and pharmacodynamic profiles of certain PPIs may affect 
the patient’s compliance and, consequently, the effective-
ness of PPIs.
Qualimetric analysis allows comparing the proton pump 
inhibitors for the pharmacokinetic and pharmacodynamic 
parameters, the safety profile, the range of available dosage 
forms and their cost [5, 6, 7, 8]. 
The basis of the qualimetric analysis is deductive-axi-
omatic approach, which allows quantifying the qualitative 
properties of drugs and determining the level of compet-
itiveness of each of them in the pharmaceutical market 
[5, 6, 7, 8].
THE AIM
The objective of the paper is to investigate the competi-
tiveness of proton pump inhibitors registered in Ukraine 
by comparing the parameters of their quality properties 
using the method of qualimetric analysis.
MATERIALS AND METHODS
The subject of the study is the 133 trade names of proton 
pump inhibitors registered in Ukraine – Omeprazole (28 
TN), Pantoprazole (54 TN), Lansoprazole (5 TN), Rabepra-
zole (15 TN), Esomeprazole (29 TN) and Dexlansoprazole 
(2 TN) [1].
Since qualitative properties of drugs are constant ob-
jective parameters, the qualimetric analysis was carried 
out by the non-expert (also known as analytical) method. 
The qualimetric analysis included the following steps: 1) 
determining the property indicators characterizing the 
PPIs and creating a so-called «property tree» in the table 
QUALIMETRIC ANALYSIS OF PROTON PUMP INHIBITORS 
IN UKRAINE
Olha V. Makarenko, Malika M. Karimova, Alona M. Masheiko, Nataliia M. Onul
STATE INSTITUTION “DNIPROPETROVSK MEDICAL ACADEMY OF HEALTH MINISTRY OF UKRAINE”, DNIPROPETROVSK, UKRAINE
ABSTRACT
Introduction: On the pharmaceutical market of Ukraine, there are six international non-proprietary names of proton pump inhibitors (PPIs) – Omeprazole, Pantoprazole, 
Lansoprazole, Rabeprazole, Esomeprazole, Dexlansoprazole, which differ in a number of pharmacokinetic and pharmacodynamic parameters, safety profile, range of dosage 
forms and their cost. 
The aim: To investigate the competitiveness of proton pump inhibitors registered in Ukraine by comparing the parameters of their quality properties using the method of 
qualimetric analysis.
Materials and methods: Qualimetric analysis is based on the deductive-axiomatic approach, which allows quantifying the qualitative properties of drugs and determining 
the degree of competitiveness of each of them in the pharmaceutical market of Ukraine. The qualitative properties of PPIs in terms of consumer are efficacy, safety, convenience 
of use and cost. The subject of the study was 133 trademarks of PPIs registered in Ukraine.
Results: The highest qualimetric values were obtained by omeprazole (Kk = 0.73) and its S-isomer esomeprazole (Kk = 0.66). Pantoprazole was inferior to them to a certain 
extent (Kk = 0.64). Lansoprazole (Kk = 0.53), rabeprazole (Kk = 0.50) and dexlansoprazole (Kk = 0.44) had the lowest values of the quality indices.
Conclusions: According to the results of the study of the PPIs’ competitiveness for parameters characterizing efficacy, safety, convenience of use and cost, assessed by qualimetric 
analysis, it has been established that the most completely and qualitatively satisfying consumer’s needs are omeprazole and its S-isomer, esomeprazole.
  KEY WORDS:  Competitiveness, Proton pump inhibitors, Pharmaceutical market, Qualimetric analysis, Ukraine
Wiad Lek 2019, 72, 9 cz II, 1769-1773
ORIGINAL ARTICLE
PRACA ORYGINALNA
Olha V. Makarenko et al. 
1770
To bring the values  of absolute property indices to one 
unit of measurement and provide their comparability among 
themselves, the conversion of absolute indices into relative 
ones was carried out using the rationing operation [8]:
  
Where  Kij – the relative index value;
Qij – the absolute property index value;
 – reference value of the absolute property index;
 – acceptable value of the absolute property index.
The quality index (Kk) of PPIs was calculated as arith-
metic average by the formula [6, 8]:
  
Where  Kk – the quality index;
G’i – the property weight factor;
Kij –  the relative index value;
n – the number of indicators of the object properties 
taken into account.
Table II presents the results of a qualitative analysis of PPIs.
Thus, it was found that omeprazole (Kk = 0.73) and esome-
prazole (Kk = 0.66) had the highest qualimetric rating. Pan-
toprazole was inferior to them to a certain extent (Kk = 0.64).
Lansoprazole (Kk = 0.53), rabeprazole (Kk = 0.50) and 
dexlansoprazole (Kk = 0.44) had the lowest values of the 
quality indices.
DISCUSSION 
This study was conducted to quantify the competitive 
advantages of IPPs.
The quality index is a complex parameter that represents 
the sum of intermediate indicators – the quality indices of 
efficacy, safety, convenience of use and cost.
Thus, it was found that the highest quality index of 
efficacy, had esomeprazole (Kk efficacy = 0.22). This is due to 
the high bioavailability (89 %) of esomeprazole, the fast 
achievement of the peak concentration of the drug in the 
blood (1-2 hours), the high antisecretory effect (24-hour 
median intragastric pH is 4.8±0.7) and the duration of 
pH > 4 in the stomach during 15,5 hours (64.6%±15.2).
Lansoprazole (Kk efficacy = 0.20) is slightly inferior to esome-
prazole in terms of the quality index of efficacy. The only com-
petitive advantage of lansoprazole compared to esomeprazole 
is large quantity of the clinical indications for use (10 vs. 7). 
Unlike esomeprazole, lansoprazole is recommended for heal-
ing of active benign gastric ulcer and active duodenal ulcer, 
maintenance of healed duodenal ulcers in adults [13, 16].
Dexlansoprazole, the proton pump inhibitor of the last 
generation, ranks third in terms of the quality index of 
efficacy (Kk efficacy = 0.17). Despite the competitive values of 
pharmacokinetic and pharmacodynamic parameters, dex-
lansoprazole has only three indications – healing of erosive 
esophagitis, maintenance of healed erosive esophagitis and 
treatment of symptomatic non-erosive gastroesophageal 
reflux disease [13, 20].
form; 2) calculating the values of the weight factors of the 
individual properties; 3) defining the values of absolute 
property indices including reference and acceptable values 
for property indices; 5) bringing the values of absolute 
property indices to one unit of measure (relative property 
indices); 6) defining the values of objects quality indices; 
7) the ranking of PPIs [6, 8].
RESULTS
The qualitative properties of PPIs in terms of consumer are 
efficacy, safety, convenience of use and cost.
Indicators that characterize the efficacy of PPIs were the 
following pharmacokinetic and pharmacodynamic pa-
rameters, such as the absolute bioavailability, the median 
time to reach to Cmax (tmax), 24-hour median intragastric 
pH, the mean percent duration of time with intragastric 
pH > 4 and the number of clinical indications approved in 
the instructions for the medical use of PPIs.
Indicators that characterize PPIs’ safety were PPIs acid 
trapping, the number of adverse reactions that may occur 
at a frequency of ≥ 1%, the possibility of appointment in he-
patic and renal insufficiency without dose adjustments, the 
possibility of use for children and elderly, the possibility of 
use for pregnant women and women during breastfeeding.
Indicators characterizing PPIs’ convenience of use were the 
market availability of brand-name drugs, generics, OTC-
drugs, registration of parenteral dosage forms and children’s 
medical forms, the number of registered doses in Ukraine.
The average cost of the oral dose was chosen as an indi-
cator that characterize PPIs’ cost.
The property weight factors were determined by the 
Delphi method with the participation of five experts and 
calculated according to the formula [8]:
  
 Where G’i – the property weight factor;
G”i – the weight of the individual properties for 5-point 
scale;
∑G”i – the total value of the weight of the individual 
properties.
It was established, that the most significant property 
weight factors of PPIs were 24-hour intragastric pH, the 
mean percent duration of time with intragastric pH > 4, 
the number of clinical indications and the possibility of 
use for children (G’i = 0.06).
“Tree of properties” and the property weight factors of 
PPIs are provided in Table I.
The value of absolute property indices – efficacy, safety 
and convenience of use were determined by the docu-
mentary method with instructions for the drug’s use. The 
value of the cost absolute property was determined by 
the calculation method. Quantitative assessment of the 
absolute property indices were carried out on a scale of 
absolute values [8].
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The lowest value of the quality index of efficacy was es-
tablished for rabeprazole (Kk efficacy = 0.13), which is due to 
the lack of competitive advantages of its pharmacodynamic 
and pharmacokinetic parameters compared to other IPPs.
Calculation results of the quality index of safety showed 
that omeprazole (Kk safety = 0.28) and its S-isomer esomepra-
zole (Kk safety = 0.25) were identified as the safest. These drugs, 
unlike other PPIs, are allowed during pregnancy [15–20].
The lowest value of the quality index of safety was found 
in rabeprazole (Kk safety = 0.16). Due to low acid trapping (pKa 
= 4.9), rabeprazole has limited use in pediatric practice [12, 
18]. The ability of rabeprazole to work in a wide range of pH 
enables it to inhibit proton pump of the immune system cells 
[3, 14], which causes a number of specific adverse reactions, 
in particular, Flu-like symptoms, infections and inflamma-
tion of the throat and lining of the nose [18].
It is necessary to mention that all PPIs may be prescribed for 
hepatic and renal insufficiency without dose adjustment [15-20].
According to the quality index of convenience of use, it 
has been found that the most fully satisfying the needs 
of consumers are drugs of omeprazole (Kk convenience = 0.24) 
and pantoprazole (Kk convenience = 0.22) registered in Ukraine. 
In particular, OTC-forms of these drugs are available for 
consumers.
It should be noted that in Ukraine there are very limited 
presented children’s dosage forms of IPPs. Among the IPPs 
registered in Ukraine in the form of powder or granules for 
preparing oral suspensions, only omeprazole is available in 
one trade name of Indian production. In addition, a dis-
tinctive feature of the pharmaceutical market in Ukraine 
is non-availability of the brand-name drugs of omeprazole 
and lansoprazole.
Drugs of omeprazole (Kk cost = 0.05) have a competitive 
advantage in terms of the quality index of cost, which is 
due to the low average cost of the oral dose. The drugs of 
lansoprazole, rabeprazole and pantoprazole follow ome-
Table I. The property weight factors of PPIs
Property indicators The weight of the criterion for 5-point scale (average value), G”i
The property weight factor,
G’i
Efficacy 
The absolute bioavailability, % 3,80 0,05
The median time (Tmax)  
to peak plasma concentrations (Cmax), h
3,40 0,05
24-hour median intragastric pH 4,40 0,06
Mean percent duration of time with intragastric  
pH > 4, %
4,80 0,06
Clinical indications, units. 4,80 0,06
Safety 
Acid trapping   (pКа) 3,00 0,04
Number of most common adverse reactions in adults 
(incidence ≥ 1 %)
3,80 0,05
The possibility of use in liver failure 3,40 0,05
The possibility of use in renal failure 3,40 0,05
The possibility of use for  children under 12 years 4,40 0,06
Possibility of use for  elderly people without dose 
adjustment
2,60 0,03
Possibility of use for pregnant women 4,00 0,05
Possibility  of use for women during breastfeeding 3,80 0,05
Convenience of use
Registration of brand-name drugs in Ukraine 4,00 0,05
Registration of generics in Ukraine 3,60 0,05
Registration of OTC-drugs in Ukraine 4,00 0,05
Registration of parenteral dosage forms 3,60 0,05
Registration of children’s medical forms 3,60 0,05
Number of registered doses, units. 3,00 0,04
Cost
The average cost of the oral dose, UAH. 3,60 0,05
TOTAL ∑G”і  = 75,00 1,00
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Table II. Results of qualimetric analysis of proton pump inhibitors in Ukraine
Indicators of qualitative properties
Reference 
value,
 
Acceptable 
value,
 
INN
Omeprazole Lansoprazole Pantoprazole Rabeprazole Esomeprazole
Dexlansopra-
zole
Efficacy
The absolute 
bioavailability, %
absolute
90 50
60*
[9, 15]
80-90  
[9, 16]
77 
[9, 17]
52 
[9, 18]
89*
[19]
Not found
[11, 20]
relative 0,25 0,75 0,68 0,05 0,98 0,75
The median time 
(Tmax) to peak plasma 
concentrations (Cmax), h
absolute
1 5
1.5 (1-2) 
[15]
1.75 (1.5-2) 
[16]
2.5 
[9, 17]
3.5 (2-5)
[9, 18]
1.5 (1-2) 
[19]
1.5 (1-2; 4-5)  
[11, 20]
relative 0,88 0,81 0,63 0,38 0,88 0,88
Mean intragastric 
pH±standard deviation 
over 24 h after multiple 
doses of PPIs for healthy 
volunteers
absolute
5.5 2.1
3.5±1.0  
[10]
4.1±0.7  
[10]
3.5±1.4  
[10]
4.5±0.5
[10]
4.8±0.7
[10]
4.55
[20]
relative 0,41 0,59 0,40 0,71 0,79 0,72
Mean percent duration 
of time with intragastric 
pH > 4 after multiple 
doses  
of PPIs %
absolute
79,8 28,2
48.7±20.5
[10]
55.1±14.4
[10]
53.6±19.8
[10]
57.7±14.2
[10]
64.6±15.2
[10]
71 
[20]
relative 0,40 0,52 0,49 0,57 0,71 0,83
Indications, units 
absolute
10 3
10 [4, 15] 10 [4, 16] 7 [4, 17] 7 [4, 18] 7 [4, 19] 3 [4, 20]
relative 1,00 1,00 0,57 0,57 0,57 0,00
The quality index of 
efficacy, Kk efficacy
0,17 0,20 0,15 0,13 0,22 0,17
Safety
Acid trapping (pКа)
absolute
3,0 5,0
4,13 [12] 4,01 [12] 3,96 [12] 4,9 [12] 4,13 [12, 21] 4,01 [12]
relative 0,44 0,50 0,52 0,05 0,44 0,5
Number of most common 
adverse reactions in adults 
(incidence ≥ 1 %)
absolute
1 10
6 [15] 4 [16] 7 [17] 5 [18] 6 [19] 5 [20]
relative 0,44 0,67 0,33 0,56 0,44 0,56
The possibility of use in 
liver failure without dose 
adjustment
absolute
Yes No
Yes [15] Yes [16] Yes [17] Yes [18] Yes [19] Yes [20]
relative 1,00 1,00 1,00 1,00 1,00 1,00
The possibility of use in 
renal failure without dose 
adjustment
absolute
Yes No
Yes [15] Yes [16] Yes [17] Yes [18] Yes [19] Yes [20]
relative 1,00 1,00 1,00 1,00 1,00 1,00
The possibility of use for  
children under 12 years
absolute
Yes No
Yes [4, 15] Yes [4, 16] Yes [4, 17] No [4, 18] Yes [4, 19] No [4, 20]
relative 1,00 1,00 1,00 0,00 1,00 0,00
Possibility of use for  
elderly people without 
dose adjustment
absolute
Yes No
Yes [15] No [16] Yes [17] Yes [18] Yes [19] Yes [20]
relative 1,00 0,00 1,00 1,00 1,00 0,00
Possibility of use for 
pregnant women 
absolute
Yes No
Yes [15] No [16] No [17] No [18] Risk/benefit [19] No [20]
relative 1,0 0,00 0,00 0,00 0,5 0,00
Possibility  of use for women 
during breastfeeding
absolute
Yes No
No [15] No [16] No [17] No [18] No [19] No [20]
relative 0,00 0,00 0,00 0,00 0,00 0,00
The quality index of 
safety, Kk safety
0,28 0,21 0,23 0,16 0,25 0,18
Convenience of use
Registration of brand-
name drugs in Ukraine 
absolute
Yes No
No [1] No [1] Yes [1] Yes [1] Yes [1] Yes [1]
relative 0,0 0,0 1,0 1,0 1,0 1,0
Registration of generics 
in Ukraine
absolute
Yes No
Yes [1] Yes [1] Yes [1] Yes [1] Yes [1] No [1]
relative 1,0 1,0 1,0 1,0 1,0 0,0
Registration of OTC-
drugs in Ukraine
absolute
Yes No
Yes [1] No [1] Yes [1] No [1] No [1] No [1]
relative 1,0 0,0 1,0 0,0 0,0 0,0
Registration of parenteral 
dosage forms in Ukraine
absolute
Yes No
Yes [1] No [1] Yes [1] Yes [1] Yes [1] No [1]
relative 1,0 0,0 1,0 1,0 1,0 0,0
Registration of 
children’s medical forms 
(suspension for oral use)
absolute
Yes No
Yes [1] No [1] No [1] No [1] No [1] No [1]
relative 1,0 0,0 0,0 0,0 0,0 0,0
Number of registered 
doses, units.
absolute
3 1
3 [1] 2 [1] 2 [1] 2 [1] 2 [1] 2 [1]
relative 1,0 0,5 0,5 0,5 0,5 0,5
The quality index of 
convenience of use,  
Kk convenience
0,24 0,07 0,22 0,17 0,17 0,07
Сost
The average cost of the 
oral dose, UAH.
absolute
2,00 20,00
20 mg-
2,15 [22]
30 mg -
4,07 [22]
20 mg -
6,16 [22]
20 mg -
5,44 [22]
20 mg -
13,09 [22]
30 mg -
13,99 [22]
relative 0,99 0,89 0,77 0,81 0,25 0,33
The quality index of 
cost, Kk cost
0,05 0,04 0,04 0,04 0,01 0,02
The quality index, Kk 0,73 0,53 0,64 0,50 0,66 0,44
Rank  1 4 3 5 2 6
Note: *  – the absolute bioavailability of repeated doses.
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prazole. Drugs of esomeprazole and dexalanesoprazole 
have the highest average cost of the oral dose.
CONCLUSIONS
According to the results of the study of the PPIs’ com-
petitiveness for parameters characterizing efficacy, safety, 
convenience of use and cost, assessed by qualimetric anal-
ysis, it has been established that the most completely and 
qualitatively satisfying consumer’s needs are omeprazole 
and its S-isomer, esomeprazole.
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